RICHMOND, Calif., May 20, 2024 /PRNewswire/ -- SunPower (NASDAQ:SPWR) received on May 17, 2024, a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"), which requires timely filing of all required periodic financial reports with the Securities and Exchange Commission (the "SEC"), as a result of not having timely filed its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024 (the "Q1 2024 10-Q") with the SEC, as described more fully in the Company's Notification of Late Filing on ...

Net revenue of $1.5 billion decreased 1.7 percent year over year Comparable sales declined 1.2 percent year over year and increased 4.1 percent on a two-year basis GAAP net loss of $46.5 million, or $(0.17) per share, compared to GAAP net loss of $1.9 million, or $(0.01) per share in the prior yearAdjusted Net Income1 of $(11.8) million, or $(0.04) per share, compared to $14.9 million, or $0.06 per share in the prior yearAdjusted EBITDA1 of $75.6 million compared to $111.0 million in the prior yearOperating Cash Flow of $(8.4) million compared to $37.7 million in the prior yearFree Cash ...

SINGAPORE, May 21, 2024 /PRNewswire/ -- Maxeon Solar Technologies, Ltd. (NASDAQ: MAXN) (the "Company"), a global leader in solar innovation and channels, announced that on May 17, 2024, it received a notice of non-compliance (the "Notice") from the Nasdaq Global Select Market ("Nasdaq") stating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) ("Listing Rule") because the Company did not timely file its annual report for the fiscal year ended December 31, 2023 on Form 20-F (the "Annual Report") with the Securities and Exchange Commission (the "SEC").

Enrollment completed and on track to present data from COM701 + COM902 + pembrolizumab platinum resistant ovarian cancer study in Q4 2024Data from COM701 + COM902 + pembrolizumab study in microsatellite stable colorectal cancer with liver metastases planned to be presented at ASCO 2024 annual meetingOn track to submit IND for COM503 in the second half of 2024 with preparation for Phase 1 study well advancedPartner, AstraZeneca, progressed rilvegostomig into second Phase 3 trial in nonsquamous NSCLC; Compugen eligible for development milestone payments for this second indicationSolid balance sheet with extended cash runway expected to fund operations into 2027HOLON, Israel, May 20, 2024 /PRNewswire/ ...